Characterization Of Oncogenes And Assays Based Thereon


Ontology type: sgo:Patent     


Patent Info

DATE

1984-04-12T00:00

AUTHORS

WEINBERG ROBERT A , TABIN CLIFFORD JAMES , BRADLEY SCOTT M

ABSTRACT

Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, serological reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0601", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "WEINBERG ROBERT A", 
        "type": "Person"
      }, 
      {
        "name": "TABIN CLIFFORD JAMES", 
        "type": "Person"
      }, 
      {
        "name": "BRADLEY SCOTT M", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/298343a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000056327", 
          "https://doi.org/10.1038/298343a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/297474a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040641632", 
          "https://doi.org/10.1038/297474a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/297479a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020097808", 
          "https://doi.org/10.1038/297479a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/289607a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013345185", 
          "https://doi.org/10.1038/289607a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1984-04-12T00:00", 
    "description": "

Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, serological reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.

", "id": "sg:patent.WO-1984001389-A1", "name": "CHARACTERIZATION OF ONCOGENES AND ASSAYS BASED THEREON", "recipient": [ { "id": "http://www.grid.ac/institutes/grid.116068.8", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/WO-1984001389-A1" ], "sdDataset": "patents", "sdDatePublished": "2022-08-04T17:25", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/patent/patent_49.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.WO-1984001389-A1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.WO-1984001389-A1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.WO-1984001389-A1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.WO-1984001389-A1'


 

This table displays all metadata directly associated to this object as RDF triples.

49 TRIPLES      14 PREDICATES      19 URIs      8 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.WO-1984001389-A1 schema:about anzsrc-for:06
2 anzsrc-for:0601
3 schema:author Nb174d19f14074a47b32a1977a816ba7e
4 schema:citation sg:pub.10.1038/289607a0
5 sg:pub.10.1038/297474a0
6 sg:pub.10.1038/297479a0
7 sg:pub.10.1038/298343a0
8 schema:datePublished 1984-04-12T00:00
9 schema:description <p>Experiments designed to define the differences between the 21 oncogene of DNA isolated from human bladder cancer cells and its corresponding proto-oncogene. By a series of in vitro recombinations, the difference was initially isolated to a 350 kb segment of DNA; sequencing defined the difference as a change in the Gly12 codon causing the p21 protein of the oncogene to contain valine at a location where the p21 protein of the proto-oncogene contained glycine. Assays for detecting carcinogenesis based on such differences are also described. In one type of assay, a restriction enzyme specific for either the altered or non-altered DNA segment of the genes are employed to detect carcinogenesis. In another type of assay, serological reagents, such as antibody specific for either p21 protein expressed from the proto-oncogene or oncogene, or a common site therein, are described.</p>
10 schema:name CHARACTERIZATION OF ONCOGENES AND ASSAYS BASED THEREON
11 schema:recipient grid-institutes:grid.116068.8
12 schema:sameAs https://app.dimensions.ai/details/patent/WO-1984001389-A1
13 schema:sdDatePublished 2022-08-04T17:25
14 schema:sdLicense https://scigraph.springernature.com/explorer/license/
15 schema:sdPublisher N07b95697100746079abb20a4b5035b18
16 sgo:license sg:explorer/license/
17 sgo:sdDataset patents
18 rdf:type sgo:Patent
19 N07b95697100746079abb20a4b5035b18 schema:name Springer Nature - SN SciGraph project
20 rdf:type schema:Organization
21 N57251f23915946fe81276128b7fe7775 schema:name BRADLEY SCOTT M
22 rdf:type schema:Person
23 N63f6e021a3384a4aa0815ad91e27b111 schema:name TABIN CLIFFORD JAMES
24 rdf:type schema:Person
25 Nb174d19f14074a47b32a1977a816ba7e rdf:first Nf3cd316d1e454487a22af53b8c1ea04c
26 rdf:rest Nfcb2c487849e4667920c1f615df826a1
27 Nd27b1104f1f64db883908fc4dfdb553e rdf:first N57251f23915946fe81276128b7fe7775
28 rdf:rest rdf:nil
29 Nf3cd316d1e454487a22af53b8c1ea04c schema:name WEINBERG ROBERT A
30 rdf:type schema:Person
31 Nfcb2c487849e4667920c1f615df826a1 rdf:first N63f6e021a3384a4aa0815ad91e27b111
32 rdf:rest Nd27b1104f1f64db883908fc4dfdb553e
33 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
34 rdf:type schema:DefinedTerm
35 anzsrc-for:0601 schema:inDefinedTermSet anzsrc-for:
36 rdf:type schema:DefinedTerm
37 sg:pub.10.1038/289607a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013345185
38 https://doi.org/10.1038/289607a0
39 rdf:type schema:CreativeWork
40 sg:pub.10.1038/297474a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040641632
41 https://doi.org/10.1038/297474a0
42 rdf:type schema:CreativeWork
43 sg:pub.10.1038/297479a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020097808
44 https://doi.org/10.1038/297479a0
45 rdf:type schema:CreativeWork
46 sg:pub.10.1038/298343a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000056327
47 https://doi.org/10.1038/298343a0
48 rdf:type schema:CreativeWork
49 grid-institutes:grid.116068.8 schema:Organization
 




Preview window. Press ESC to close (or click here)


...